Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Newly published research provides the first demonstration of how a genetic mutation associated with a common form of albinism leads to the lack of melanin pigments that characterizes the condition.
Columbia University Medical Center (CUMC) researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss.
Researchers at the National Eye Institute (NEI) have described the functions of a gene responsible for anchoring cilia — sensory hair-like extensions present on almost every cell of the body.
Researchers have made progress toward an approach that would use light-sensitive drugs to stimulate cells in the retina and restore vision to people who are blind or visually impaired.
By borrowing a tool from bacteria that infect plants, scientists have developed a new approach to eliminate mutated DNA inside mitochondria—the energy factories within cells.
On February 14, 2013, the U.S. Food and Drug Administration approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP).
Erik Weihenmayer has climbed mountains around the world - the highest peaks, in fact, on every continent. One afternoon a few years ago, however, a climbing wall in a local gym served as the setting of a most memorable journey.
Docosahexaenoic acid (DHA) supplementation at a dose of 1200 milligrams per day for four years did not, on average, slow the course of retinitis pigmentosa (RP) in adult RP patients already taking vitamin A supplements..